{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T14:27:36Z","timestamp":1793975256141,"version":"4.8.0"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,3,25]],"date-time":"2019-03-25T00:00:00Z","timestamp":1553472000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","award":["Operating grant - IHS 120272"],"award-info":[{"award-number":["Operating grant - IHS 120272"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Nephrol"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1186\/s12882-019-1280-7","type":"journal-article","created":{"date-parts":[[2019,3,25]],"date-time":"2019-03-25T13:02:41Z","timestamp":1553518961000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":28,"title":["Statin use and the risk of acute kidney injury in older adults"],"prefix":"10.1186","volume":"20","author":[{"name":"for the Alberta Kidney Disease Network","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0846-3187","authenticated-orcid":false,"given":"Marcello","family":"Tonelli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anita M.","family":"Lloyd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aminu K.","family":"Bello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew T.","family":"James","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott W.","family":"Klarenbach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Finlay A.","family":"McAlister","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Braden J.","family":"Manns","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ross T.","family":"Tsuyuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brenda R.","family":"Hemmelgarn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,3,25]]},"reference":[{"key":"1280_CR1","doi-asserted-by":"publisher","first-page":"1670","DOI":"10.1016\/S0140-6736(10)61350-5","volume":"376","author":"C Baigent","year":"2010","unstructured":"Cholesterol Treatment Trialists C, Baigent C, Blackwell L, Emberson J, Holland LE, Reith C, Bhala N, Peto R, Barnes EH, Keech A, Simes J, Collins R, de Lemos J, Braunwald E, Blazing M, Murphy S, Downs JR, Gotto A, Clearfield M, Holdaas H, Gordon D, Davis B, Koren M, Dahlof B, Poulter N, Sever P, Knopp RH, Fellstrom B, Holdaas H, Jardine A, Schmieder R, Zannad F, Goldbourt U, Kaplinsky E, Colhoun HM, Betteridge DJ, Durrington PN, Hitman GA, Fuller J, Neil A, Wanner C, Krane V, Sacks F, Moye L, Pfeffer M, Hawkins CM, Braunwald E, Barter P, Keech A, Tavazzi L, Maggioni A, Marchioli R, Tognoni G, Franzosi MG, Maggioni A, Bloomfield H, Robins S, Collins R, Armitage J, Keech A, Parish S, Peto R, Sleight P, Pedersen TR, Ridker PM, Holman R, Meade T, Simes J, Keech A, MacMahon S, Marschner I, Tonkin A, Shaw J, Serruys PW, Nakamura H, Knatterud G, Furberg C, Byington R, Macfarlane P, Cobbe S, Ford I, Murphy M, Blauw GJ, Packard C, Shepherd J, Kjekshus J, Pedersen T, Wilhelmsen L, Braunwald E, Cannon C, Murphy S, Collins R, Armitage J, Bowman L, Parish S, Peto R, Sleight P, Baigent C, Baxter A, Collins R, Landray M, La Rosa J, Rossouw J, Probstfield J, Shepherd J, Cobbe S, Macfarlane P, Ford I, Flather M, Kastelein J, Newman C, Shear C, Tobert J, Varigos J, White H, Yusuf S, Mellies M, McGovern M, Barclay J, Belder R, Mitchel MY, Musliner T, Ansquer JC, Llewellyn BM, Bortolini M, Brandrup-Wognsen G, Bryzinski B, Olsson G, Pears J, DeMicco D, Baxter A, Baigent C, Barnes EH, Bhala N, Blackwell L, Buck G, Collins R, Emberson J, Herrington WG, Holland LE, Kearney PM, Keech A, Kirby A, Lewis DA, Marschner I, Pollicino C, Reith C, Simes J, Sourjina T. Efficacy and safety of more intensive lowering of ldl cholesterol: A meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet. 2010;376:1670\u201381.","journal-title":"Lancet"},{"key":"1280_CR2","doi-asserted-by":"publisher","first-page":"1969","DOI":"10.1001\/jama.2016.16557","volume":"316","author":"PD Thompson","year":"2016","unstructured":"Thompson PD. What to believe and do about statin-associated adverse effects. Jama. 2016;316:1969\u201370.","journal-title":"Jama."},{"key":"1280_CR3","doi-asserted-by":"publisher","first-page":"2395","DOI":"10.1016\/j.jacc.2016.02.071","volume":"67","author":"PD Thompson","year":"2016","unstructured":"Thompson PD, Panza G, Zaleski A, Taylor B. Statin-associated side effects. J Am Coll Cardiol. 2016;67:2395\u2013410.","journal-title":"J Am Coll Cardiol"},{"key":"1280_CR4","first-page":"20","volume":"27","author":"DA Hennessy","year":"2016","unstructured":"Hennessy DA, Tanuseputro P, Tuna M, Bennett C, Perez R, Shields M, Ko DT, Tu J, Manuel DG. Population health impact of statin treatment in Canada. Health Rep. 2016;27:20\u20138.","journal-title":"Health Rep"},{"key":"1280_CR5","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1159\/000441426","volume":"131","author":"MT James","year":"2015","unstructured":"James MT, Pannu N. Can acute kidney injury be considered a clinical quality measure. Nephron. 2015;131:237\u201341.","journal-title":"Nephron."},{"key":"1280_CR6","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1111\/j.1525-139X.2011.00836.x","volume":"24","author":"MT James","year":"2011","unstructured":"James MT. Tonelli M, Alberta kidney disease N. Financial aspects of renal replacement therapy in acute kidney injury. Semin Dial. 2011;24:215\u20139.","journal-title":"Semin Dial"},{"key":"1280_CR7","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1097\/MNH.0b013e3280dd8c35","volume":"16","author":"SS Waikar","year":"2007","unstructured":"Waikar SS, Liu KD, Chertow GM. The incidence and prognostic significance of acute kidney injury. Curr Opin Nephrol Hypertens. 2007;16:227\u201336.","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"1280_CR8","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1681\/ASN.2010050442","volume":"22","author":"AO Molnar","year":"2011","unstructured":"Molnar AO, Jain AK, Kitchlu A, Siddiqui N, Garg AX, Coca SG, Parikh CR, Devereaux PJ, Walsh M, Luo J, Michael Paterson J, Wald R. Statin use associates with a lower incidence of acute kidney injury after major elective surgery. J Am Soc Nephrol. 2011;22:939\u201346.","journal-title":"J Am Soc Nephrol"},{"key":"1280_CR9","doi-asserted-by":"publisher","first-page":"f880","DOI":"10.1136\/bmj.f880","volume":"346","author":"CR Dormuth","year":"2013","unstructured":"Dormuth CR, Hemmelgarn BR, Paterson JM, James MT, Teare GF, Raymond CB, Lafrance J-P, Levy A, Garg AX, Ernst P, Canadian Network for Observational Drug Effect S, Suissa S, Henry D, Paterson M, Colin D, Hemmelgarn B, Teare G, Martens P, Caetano P, Ernst P, LeLorier J, Platt R, Levy A. Use of high potency statins and rates of admission for acute kidney injury: Multicenter, retrospective observational analysis of administrative databases. Bmj. 2013;346:f880.","journal-title":"Bmj"},{"key":"1280_CR10","doi-asserted-by":"publisher","first-page":"c2197","DOI":"10.1136\/bmj.c2197","volume":"340","author":"J Hippisley-Cox","year":"2010","unstructured":"Hippisley-Cox J, Coupland C. Unintended effects of statins in men and women in England and wales: population based cohort study using the qresearch database. Bmj. 2010;340:c2197.","journal-title":"Bmj."},{"key":"1280_CR11","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1186\/1471-2369-10-30","volume":"10","author":"BR Hemmelgarn","year":"2009","unstructured":"Hemmelgarn BR, Clement F, Manns BJ, Klarenbach S, James MT, Ravani P, Pannu N, Ahmed SB, MacRae J, Scott-Douglas N, Jindal K, Quinn R, Culleton BF, Wiebe N, Krause R, Thorlacius L, Tonelli M. Overview of the Alberta kidney disease network. BMC Nephrol. 2009;10:30.","journal-title":"BMC Nephrol"},{"key":"1280_CR12","unstructured":"National Institute for Health and Clinical Excellence. Lipid modification: Cardiovascular risk assessment and the modification of blood lipids for the primary and secondary prevention of cardiovascular disease. 2014."},{"key":"1280_CR13","doi-asserted-by":"publisher","first-page":"604","DOI":"10.7326\/0003-4819-150-9-200905050-00006","volume":"150","author":"AS Levey","year":"2009","unstructured":"Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF 3rd, Feldman HI, Kusek JW, Eggers P, Van Lente F, Greene T, Coresh J. A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009;150:604\u201312.","journal-title":"Ann Intern Med"},{"key":"1280_CR14","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1186\/s12911-015-0155-5","volume":"15","author":"M Tonelli","year":"2015","unstructured":"Tonelli M, Wiebe N, Fortin M, Guthrie B, Hemmelgarn BR, James MT, Klarenbach SW, Lewanczuk R, Manns BJ, Ronksley P, Sargious P, Straus S, Quan H, Alberta Kidney Disease N. Methods for identifying 30 chronic conditions: Application to administrative data. BMC Med Inform Decis Mak. 2015;15:31.","journal-title":"BMC Med Inform Decis Mak"},{"key":"1280_CR15","doi-asserted-by":"publisher","first-page":"1688","DOI":"10.1681\/ASN.2006010073","volume":"17","author":"SS Waikar","year":"2006","unstructured":"Waikar SS, Wald R, Chertow GM, Curhan GC, Winkelmayer WC, Liangos O, Sosa M-A, Jaber BL. Validity of international classification of diseases, ninth revision, clinical modification codes for acute renal failure. J Am Soc Nephrol. 2006;17:1688\u201394.","journal-title":"J Am Soc Nephrol"},{"key":"1280_CR16","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1002\/pds.1230","volume":"15","author":"SE Andrade","year":"2006","unstructured":"Andrade SE, Kahler KH, Frech F, Chan KA. Methods for evaluation of medication adherence and persistence using automated databases. Pharmacoepidemiol Drug Saf. 2006;15:565\u201374 discussion 575-567.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"1280_CR17","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.1080\/03610910902859574","volume":"38","author":"PC Austin","year":"2009","unstructured":"Austin PC. Using the standardized difference to compare the prevalence of a binary variable between two groups in observational research. Commun Stat-Simul C. 2009;38:1228\u201334.","journal-title":"Commun Stat-Simul C"},{"key":"1280_CR18","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1002\/pds.3500","volume":"22","author":"JB Layton","year":"2013","unstructured":"Layton JB, Brookhart MA, Jonsson Funk M, Simpson RJ Jr, Pate V, Sturmer T, Kshirsagar AV. Acute kidney injury in statin initiators. Pharmacoepidemiol Drug Saf. 2013;22:1061\u201370.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"1280_CR19","doi-asserted-by":"publisher","first-page":"2181","DOI":"10.1016\/S0140-6736(11)60739-3","volume":"377","author":"C Baigent","year":"2011","unstructured":"Baigent C, Landray MJ, Reith C, Emberson J, Wheeler DC, Tomson C, Wanner C, Krane V, Cass A, Craig J, Neal B, Jiang L, Hooi LS, Levin A, Agodoa L, Gaziano M, Kasiske B, Walker R, Massy ZA, Feldt-Rasmussen B, Krairittichai U, Ophascharoensuk V, Fellstrom B, Holdaas H, Tesar V, Wiecek A, Grobbee D, de Zeeuw D, Gronhagen-Riska C, Dasgupta T, Lewis D, Herrington W, Mafham M, Majoni W, Wallendszus K, Grimm R, Pedersen T, Tobert J, Armitage J, Baxter A, Bray C, Chen Y, Chen Z, Hill M, Knott C, Parish S, Simpson D, Sleight P, Young A, Collins R, on behalf of the SHARP Investigators. The effects of lowering ldl cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (study of heart and renal protection): A randomised placebo-controlled trial. Lancet. 2011;377:2181\u201392.","journal-title":"Lancet"},{"key":"1280_CR20","unstructured":"Roberts MD. Crestor (rosuvastatin calcium) nda 21-366 jupiter. Endocrinologic and Metabolic Drugs Advisory Committee Meeting. 2009."},{"key":"1280_CR21","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.114.000784","volume":"3","author":"A Sarma","year":"2014","unstructured":"Sarma A, Cannon CP, de Lemos J, Rouleau JL, Lewis EF, Guo J, Mega JL, Sabatine MS, O'Donoghue ML. The incidence of kidney injury for patients treated with a high-potency versus moderate-potency statin regimen after an acute coronary syndrome. J Am Heart Assoc. 2014;3:e000784.","journal-title":"J Am Heart Assoc"},{"key":"1280_CR22","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1001\/jama.2016.0548","volume":"315","author":"FT Billings","year":"2016","unstructured":"Billings FT, Hendricks PA, Schildcrout JS, Shi Y, Petracek MR, Byrne JG, Brown NJ. High-dose perioperative atorvastatin and acute kidney injury following cardiac surgery: a randomized clinical trial. Jama. 2016;315:877\u201388.","journal-title":"Jama."},{"key":"1280_CR23","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.ahj.2016.01.016","volume":"176","author":"C Reith","year":"2016","unstructured":"Cholesterol Treatment Trialists C, Reith C, Blackwell L, Emberson J, Mihaylova B, Armitage J, Fulcher J, Keech A, Simes J, Baigent C, Collins R. Protocol for analyses of adverse event data from randomized controlled trials of statin therapy. Am Heart J. 2016;176:63\u20139.","journal-title":"Am Heart J"},{"key":"1280_CR24","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1358\/mf.2003.25.6.769652","volume":"25","author":"MJ Garcia","year":"2003","unstructured":"Garcia MJ, Reinoso RF, Sanchez Navarro A, Prous JR. Clinical pharmacokinetics of statins. Methods Find Exp Clin Pharmacol. 2003;25:457\u201381.","journal-title":"Methods Find Exp Clin Pharmacol"}],"container-title":["BMC Nephrology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-019-1280-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12882-019-1280-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-019-1280-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,12,3]],"date-time":"2020-12-03T13:08:41Z","timestamp":1607000921000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcnephrol.biomedcentral.com\/articles\/10.1186\/s12882-019-1280-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3,25]]},"references-count":24,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["1280"],"URL":"https:\/\/doi.org\/10.1186\/s12882-019-1280-7","relation":{},"ISSN":["1471-2369"],"issn-type":[{"value":"1471-2369","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,3,25]]},"assertion":[{"value":"16 March 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 March 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 March 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The institutional review boards at the Universities of Calgary and Alberta approved the study (REB14\u20130884, Pro00053469) with a waiver of consent granted.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"MT holds research funding from Merck, Canada (funds to institution). M.J. receives salary support from a CIHR New Investigator Award and holds an investigator-initiated research grant funded by Amgen, Canada. R.T. has the following disclosures: (Investigator-Initiated Research Grant: Merck; Speaking fees: Merck, Sandoz (Japan); President, SMHEART CONSULTING, INC.; Board of Directors, Hypertension Canada). The other authors have no conflicts of interest to disclose.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"103"}}